Atre­ca holds off de­vel­op­ment on its on­ly clin­i­cal pro­gram, cuts head­count by 40%

In a bid to ex­tend its cash run­way, Atre­ca has sus­pend­ed the clin­i­cal de­vel­op­ment of its sol­id tu­mor mon­o­clon­al an­ti­body ATRC-101, slash­ing staff num­bers by 40%. The com­pa­ny will fo­cus on its pre­clin­i­cal an­ti­body-drug con­ju­gate (ADC) as­sets in­stead.

The San Car­los, CA biotech’s Phase Ib ATRC-101 was the most ad­vanced can­di­date in its six-as­set pipeline, three of which are AD­Cs. One of its AD­Cs will be se­lect­ed as a clin­i­cal can­di­date in the com­ing months, with a pos­si­ble IND sub­mis­sion late next year at the ear­li­est.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER